Highly commended
90TEN, part of Envision Pharma Group
Summary of work
In 2023, 90TEN navigated significant internal and external challenges. Following the global pandemic and our recent acquisition, we were faced with an identity crisis. At a time when we needed to pull together as a team, we were questioning who we are. This was compounded by the departure of key leadership and the lose of a key global account due to agency consolidation by the client.
Despite all of this, we achieved an incredible 47% growth in revenue. This was only made possible by the incredible teamwork and culture that we fostered. We leaned into what made us unique, leveraging our experience in behavioural science and the development of innovative solutions. We created a hybrid, inclusive working environment that celebrated people’s individuality. We empowered the team to take greater ownership of their accounts, which allowed the roll-out of unlimited holidays and a fully flexible working framework. We incentivised the team and drove development through innovative revenue sharing schemes.
90TEN’s journey in 2023 exemplifies resilience, innovation, and client-centricity. As we look ahead, we remain committed to driving excellence, fostering collaboration, and delivering impactful results for our clients.
Judges’ comments
90TEN impressed with their honesty, charitable work and the story they told around the transition to med affairs. The foundation piece was the crown jewel in their presentation. It has clearly been a challenging time for the agency and the team were clearly confident that they would come through the adversity and triumph. Their AI work is interesting and they impressed with their sensibility and well-run agency.
